Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS news (Ticker: ARTV), a resource for investors and traders seeking the latest updates and insights on ARTIVA BIOTHERAPEUTICS stock.
Artiva Biotherapeutics develops cell therapies for autoimmune diseases and cancers, led by AlloNK® (AB-101), an allogeneic, off-the-shelf, non-genetically modified and cryopreserved NK cell therapy candidate. Company updates center on AlloNK clinical data in B-cell driven autoimmune diseases, including rheumatoid arthritis and Sjögren’s disease, and on its use with anti-CD20 monoclonal antibodies such as rituximab or obinutuzumab to drive B-cell depletion.
Recurring developments also cover quarterly and annual financial results, balance sheet disclosures, biotechnology conference participation, board and executive appointments, and equity award activity tied to Artiva’s public-company governance.
Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, has announced its participation in the 2024 Cantor Fitzgerald Global Healthcare Conference. The company's management will engage in a fireside chat on September 18, 2024, at 8:00 a.m. ET in New York City.
Investors and the public can access a live webcast of the chat through the 'Investors' section on Artivabio.com. A replay will be available for 90 days after the event. Additionally, Artiva's management team will be available for in-person investor meetings during the conference.
Artiva Biotherapeutics (Nasdaq: ARTV) reported Q2 2024 financial results and recent business highlights. Key points include:
- Successful completion of a $179.0 million upsized IPO, extending cash runway through 2026
- Initiation of an investigator-initiated basket trial exploring AlloNK® in multiple autoimmune indications
- Treatment of the first patient in a Phase 1/1b trial for lupus nephritis (LN) and systemic lupus erythematosus (SLE)
- Q2 2024 financial results: $46.6 million in cash and investments (pre-IPO), $12.3 million in R&D expenses, and a net loss of $17.8 million
Artiva aims to report initial data on autoimmune indications from ongoing trials in the first half of 2025.
Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotechnology company, announced the pricing of its upsized initial public offering (IPO) of 13,920,000 shares of common stock at $12.00 per share. This offering is expected to yield gross proceeds of approximately $167.0 million, before underwriting discounts and offering expenses. Additionally, underwriters have a 30-day option to purchase up to 2,088,000 additional shares at the IPO price. Shares will begin trading on Nasdaq under “ARTV” on July 19, 2024, with the offering closing on July 22, 2024, pending customary conditions. Jefferies, TD Cowen, and Cantor are joint book-running managers, with Wedbush PacGrow and Needham & Company as co-lead managers.